Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vilastobart by Xilio Therapeutics for Merkel Cell Carcinoma: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
Vilastobart by Xilio Therapeutics for Gastric Cancer: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
Vilastobart by Xilio Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Vilastobart by Xilio Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Vilastobart by Xilio Therapeutics for Leiomyosarcoma: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II...
Vilastobart by Xilio Therapeutics for Esophageal Cancer: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Vilastobart by Xilio Therapeutics for Uterine Cancer: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
Vilastobart by Xilio Therapeutics for Breast Cancer: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
Vilastobart by Xilio Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
XTX-101 by Xilio Therapeutics for Merkel Cell Carcinoma: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
XTX-101 by Xilio Therapeutics for Leiomyosarcoma: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II...
XTX-101 by Xilio Therapeutics for Esophageal Cancer: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
XTX-101 by Xilio Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
XTX-101 by Xilio Therapeutics for Uterine Cancer: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
XTX-101 by Xilio Therapeutics for Gastric Cancer: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
XTX-101 by Xilio Therapeutics for Cervical Cancer: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
XTX-101 by Xilio Therapeutics for Prostate Cancer: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
XTX-101 by Xilio Therapeutics for Breast Cancer: Likelihood of Approval
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase...